Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) Revenue (2020 - 2025)

Historic Revenue for Neuroone Medical Technologies (NMTC) over the last 11 years, with Q4 2025 value amounting to $2.9 million.

  • Neuroone Medical Technologies' Revenue fell 1165.28% to $2.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 million, marking a year-over-year increase of 5159.8%. This contributed to the annual value of $9.1 million for FY2025, which is 16347.19% up from last year.
  • According to the latest figures from Q4 2025, Neuroone Medical Technologies' Revenue is $2.9 million, which was down 1165.28% from $2.7 million recorded in Q3 2025.
  • Over the past 5 years, Neuroone Medical Technologies' Revenue peaked at $3.3 million during Q4 2024, and registered a low of $18240.0 during Q1 2021.
  • For the 5-year period, Neuroone Medical Technologies' Revenue averaged around $883680.6, with its median value being $548041.0 (2023).
  • As far as peak fluctuations go, Neuroone Medical Technologies' Revenue soared by 186544.67% in 2023, and later plummeted by 6329.32% in 2024.
  • Quarter analysis of 5 years shows Neuroone Medical Technologies' Revenue stood at $33748.0 in 2021, then surged by 239.51% to $114579.0 in 2022, then surged by 753.25% to $977649.0 in 2023, then skyrocketed by 234.9% to $3.3 million in 2024, then decreased by 11.65% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q4 2025, $2.7 million for Q3 2025, and $1.7 million during Q2 2025.